Lipid-based nanocarriers (liposomes) loaded with a chemotherapeutic agent and exhibiting interstitial drug release and intratumoral adhesion are disclosed. The lipid-based nanocarriers disclosed herein include an ‘adsorptive/adhesive switch’ on the nanocarriers surface with the aim to increase the tumor residence times of the drug delivery nanocarriers and to slow down their tumor clearing kinetics. The switch is designed to promote nanoparticle adsorption on cancer cells and/or the extracellular matrix (ECM) while keeping their internalization by cells to a minimum. This approach of drug delivery is key for interstitial release of highly-diffusive forms of therapeutics.

Provided herein are therapeutic oligonucleotides that comprise at least one p-ethoxy backbone linkage but no more than 80% p-ethoxy backbone linkages. Provided herein are improved delivery systems for therapeutic oligonucleotides comprising a liposome that comprises neutral phospholipids and a p-ethoxy oligonucleotide that is entrapped in the liposome.

The present disclosure describes the synthesis and use of lipid prodrugs that self-assemble into lipid microbubbles or liposomes. The prodrug-loaded microbubbles or liposomes can be activated intracellularly using an external stimulus, for example, using ultrasound waves.

A method for reducing a subcutaneous fat deposit or a visceral fat deposit in vivo by contacting the fat deposit with a composition of latanoprost encapsulated in a liposome formed solely of egg phosphatidylcholine (EggPC) or palmitoyloleoyl phosphatidylcholine (POPC). Also disclosed are methods for treating steatoblepharon, proptosis, and obstructive sleep apnea associated with excess upper airway fat by injecting into the eyelid, intraconal space, and upper airway fat deposit, respectively, the composition of latanoprost encapsulated in an EggPC or POPC liposome.

The patent discloses self-emulsifying formulations of bisphosphonates or bisphosphonic acids in the prevention and treatment of conditions involving calcium or phosphate metabolism. The dosage forms are either capsules, or tablets, or other controlled release drug delivery systems, or devices that contain self-emulsifying formulation of such bisphosphonates or bisphosphonic acids.

Disclosed are synthetic nanocarrier compositions, and related methods, comprising therapeutic protein APC presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to therapeutic proteins.

Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.

Aspects of the invention described herein relate to synthetic compounds that are useful for targeting and labeling tumor cells so as to facilitate recognition by binding agents including Chimeric Antigen Receptor T cells (CAR T cells), which are administered to a subject by intravenous or locoregional administration. Several compositions and methods of making and using these compositions to treat or inhibit a disease in a subject are contemplated.

According to one embodiment of the present invention, provided is a drug-clay mineral complex, in which the complex comprises a phospholipid, and the drug has an amine group.

Ionizable phospholipids and compositions and methods relating thereof are provided herein. In some aspects, the ionizable phospholipids provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.